Public Employees Retirement System of Ohio increased its position in Diplomat Pharmacy Inc (NYSE:DPLO) by 3,847.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 42,359 shares of the company’s stock after purchasing an additional 41,286 shares during the quarter. Public Employees Retirement System of Ohio owned approximately 0.06% of Diplomat Pharmacy worth $877,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors also recently made changes to their positions in the business. PNC Financial Services Group Inc. grew its holdings in Diplomat Pharmacy by 46.7% during the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after purchasing an additional 2,794 shares during the period. First Allied Advisory Services Inc. bought a new position in shares of Diplomat Pharmacy in the second quarter worth about $183,000. SG Americas Securities LLC bought a new position in shares of Diplomat Pharmacy in the third quarter worth about $191,000. BNP Paribas Arbitrage SA boosted its stake in shares of Diplomat Pharmacy by 57.6% in the second quarter. BNP Paribas Arbitrage SA now owns 13,992 shares of the company’s stock worth $207,000 after acquiring an additional 5,116 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in shares of Diplomat Pharmacy by 478.4% in the second quarter. Russell Investments Group Ltd. now owns 14,600 shares of the company’s stock worth $216,000 after acquiring an additional 12,076 shares during the period. Institutional investors and hedge funds own 72.21% of the company’s stock.
A number of equities analysts have recently weighed in on DPLO shares. Mizuho upped their price objective on Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 7th. Needham & Company LLC boosted their target price on Diplomat Pharmacy from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Monday, January 8th. Leerink Swann upped their price objective on Diplomat Pharmacy from $16.00 to $20.00 and gave the company a “market perform” rating in a research report on Tuesday, November 7th. BidaskClub upgraded Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 5th. Finally, Zacks Investment Research upgraded Diplomat Pharmacy from a “hold” rating to a “strong-buy” rating and set a $24.00 price objective on the stock in a research report on Tuesday, October 10th. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Diplomat Pharmacy has a consensus rating of “Buy” and an average price target of $20.94.
In other news, CFO Atul Kavthekar bought 2,000 shares of Diplomat Pharmacy stock in a transaction that occurred on Monday, November 20th. The stock was bought at an average price of $15.00 per share, for a total transaction of $30,000.00. Following the purchase, the chief financial officer now directly owns 2,000 shares of the company’s stock, valued at approximately $30,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey G. Park acquired 3,000 shares of Diplomat Pharmacy stock in a transaction on Monday, November 20th. The shares were bought at an average price of $15.46 per share, with a total value of $46,380.00. Following the purchase, the director now directly owns 7,640 shares in the company, valued at approximately $118,114.40. The disclosure for this purchase can be found here. Insiders purchased a total of 15,000 shares of company stock valued at $228,780 in the last 90 days. 30.20% of the stock is currently owned by company insiders.
Shares of Diplomat Pharmacy Inc (DPLO) opened at $25.93 on Friday. The company has a current ratio of 1.34, a quick ratio of 0.82 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $1,723.90, a price-to-earnings ratio of 259.30, a price-to-earnings-growth ratio of 3.93 and a beta of 0.62. Diplomat Pharmacy Inc has a 52-week low of $12.76 and a 52-week high of $26.17.
Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings data on Monday, November 6th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the prior year, the business posted $0.21 EPS. The business’s revenue for the quarter was down 4.8% compared to the same quarter last year. equities research analysts forecast that Diplomat Pharmacy Inc will post 0.85 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/13/public-employees-retirement-system-of-ohio-has-877000-stake-in-diplomat-pharmacy-inc-dplo.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.